company profile

We are a multi-asset, CNS-first clinical stage pharmaceutical company that grew out of an R&D team at a Big Pharma company. We are dedicated to developing novel drugs and technologies for patients suffering from neurological and psychiatric conditions.

We have a rich and growing pipeline and are currently focused on the development of safe and effective treatments to address patients’ unmet needs in Major Depressive Disorder, Parkinson’s Disease, Chronic Pain, and other conditions involving impairment of the neurological system. Our lead drug candidate is currently in a Phase 2 multicenter study in the United States. 

One of our driving principles is to invent new therapeutic modalities and bring them quickly from an idea to Proof of Concept and then to full clinical development. Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for patients.